PRLD
Prelude Therapeutics Incorporated
$1.59
+$0.02(+1.27%)
51
Overall
60
Value
66
Tech
28
Quality
Market Cap
$87.16M
Volume
111.38K
52W Range
$0.61 - $1.91
Target Price
$3.50
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | -- | -- | $7.0M | ||
| Total Revenue | -- | -- | -- | -- | $7.0M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | -- | -- | $7.0M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $58.8M | $113.7M | $123.5M | $132.3M | $146.7M | ||
| Research & Development | $48.2M | $86.8M | $92.9M | $103.4M | $118.0M | ||
| Research Expense | $48.2M | $86.8M | $92.9M | $103.4M | $118.0M | ||
| Selling, General & Administrative | $10.6M | $27.0M | $30.7M | $28.9M | $28.7M | ||
| General & Administrative Expenses | $10.6M | $27.0M | $30.7M | $28.9M | $28.7M | ||
| Salaries & Wages | -- | -- | -- | $25.6M | $21.3M | ||
| Depreciation & Amortization | $500.0K | -- | -- | -- | -- | ||
| Depreciation & Amortization | $500.0K | -- | -- | -- | -- | ||
| Other Operating Expenses | $1.2M | $1.8M | $2.1M | $132.3M | $146.7M | ||
| OPERATING INCOME | |||||||
| Operating income | $-58.8M | $-113.7M | $-123.5M | $-132.3M | $-139.7M | ||
| EBITDA | $-58.2M | $-112.8M | $-122.2M | $-118.7M | $-123.8M | ||
| NON-OPERATING ITEMS | |||||||
| Other Income/Expense | $-1.8M | $-2.0M | $8.1M | $-10.4M | $-12.5M | ||
| Other Special Charges | $1.8M | $2.0M | $8.1M | $10.4M | $12.5M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-58.8M | $-113.7M | $-123.5M | $-121.8M | $-127.2M | ||
| Pre-Tax Income | $-56.9M | $-111.7M | $-115.4M | $-121.8M | $-127.2M | ||
| NET INCOME | |||||||
| Net Income | $-56.9M | $-111.7M | $-115.4M | $-121.8M | $-127.2M | ||
| Net Income (Continuing Operations) | $-56.9M | $-111.7M | $-115.4M | $-121.8M | $-127.2M | ||
| Net Income (Discontinued Operations) | $-56.9M | $-111.7M | $-115.4M | $-121.8M | $-127.2M | ||
| Net Income (Common Stockholders) | $-56.9M | $-111.7M | $-115.4M | $-121.8M | $-127.2M | ||
| Normalized Income | -- | -- | -- | -- | $-125.9M | ||
| TOTALS | |||||||
| Total Expenses | $58.8M | $113.7M | $123.5M | $132.3M | $146.7M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $12.5M | $46.0M | $47.4M | $60.4M | $75.8M | ||
| Average Shares Outstanding (Diluted) | $12.5M | $46.0M | $47.4M | $60.4M | $75.8M | ||
| Shares Outstanding | $46.6M | $47.6M | $47.9M | $54.9M | $55.2M | ||
| Basic EPS | $-4.56 | $-2.43 | $-2.44 | $-2.02 | $-1.68 | ||
| Basic EPS (Continuing Operations) | $-4.56 | $-2.43 | $-2.44 | $-2.02 | $-1.68 | ||
| Diluted EPS | $-4.56 | $-2.43 | $-2.44 | $-2.02 | $-1.68 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.44 | $-2.02 | $-1.68 | ||
| OTHER METRICS | |||||||
| Other Gand A | $10.6M | $27.0M | $30.7M | $28.9M | $28.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRLD | $1.59 | +1.3% | 111.38K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Prelude Therapeutics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW